Altimmune ( (ALT) ) has shared an update.
On February 24, 2025, Altimmune, Inc. expanded its Board of Directors by appointing Teri Lawver and Jerome Durso, both seasoned executives in the biopharmaceutical industry. This strategic move comes as the company progresses into late-stage clinical development of pemvidutide, a promising treatment for liver and metabolic diseases. Lawver and Durso bring extensive experience in commercialization and corporate strategy, which is expected to bolster Altimmune’s efforts in transitioning to a pre-commercial-stage organization and advancing its strategic vision.
More about Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics, specifically targeting obesity and metabolic-associated steatohepatitis (MASH) with its lead product candidate, pemvidutide.
YTD Price Performance: -14.06%
Average Trading Volume: 2,565,101
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $434.6M
For detailed information about ALT stock, go to TipRanks’ Stock Analysis page.